Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, 2013. The global distribution and burden of dengue. Nature 496: 504–507.
May FJ, Davis CT, Tesh RB, Barrett AD, 2011. Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol 85: 2964–2974.
Johnson BK, Ocheng D, Gichogo A, Okiro M, Libondo D, Kinyanjui P, Tukei PM, 1982. Epidemic dengue fever caused by dengue type 2 virus in Kenya: preliminary results of human virological and serological studies. East Afr Med J 59: 781–784.
Ellis EM, Neatherlin JC, Delorey M, Ochieng M, Mohamed AH, Mogeni DO, Hunsperger E, Patta S, Gikunju S, Waiboic L, Fields B, Ofula V, Konongoi SL, Torres-Velasquez B, Marano N, Sang R, Margolis HS, Montgomery JM, Tomashek KM, 2015. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. PLoS Negl Trop Dis 9: e0003733.
Mease LE, Coldren RL, Musila LA, Prosser T, Ogolla F, Ofula VO, Schoepp RJ, Rossi CA, Adungo N, 2011. Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study. Virol J 8: 371.
Sutherland LJ, Cash AA, Huang YJ, Sang RC, Malhotra I, Moormann AM, King CL, Weaver SC, King CH, LaBeaud AD, 2011. Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med Hyg 85: 158–161.
Tigoi C, Lwande O, Orindi B, Irura Z, Ongus J, Sang R, 2015. Seroepidemiology of selected arboviruses in febrile patients visiting selected health facilities in the lake/river basin areas of Lake Baringo, Lake Naivasha, and Tana River, Kenya. Vector Borne Zoonotic Dis 15: 124–132.
LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, Borland E, Gildengorin G, Pfeil S, Teng CY, Long K, Heise M, Powers AM, Kitron U, King CH, 2015. High rates of o'nyong nyong and chikungunya virus transmission in coastal Kenya. PLoS Negl Trop Dis 9: e0003436.
Bustinduy AL, Thomas CL, Fiutem JJ, Parraga IM, Mungai PL, Muchiri EM, Mutuku F, Kitron U, King CH, 2011. Measuring fitness of Kenyan children with polyparasitic infections using the 20-meter shuttle run test as a morbidity metric. PLoS Negl Trop Dis 5: e1213.
Bisanzio D, Mutuku F, Bustinduy AL, Mungai PL, Muchiri EM, King CH, Kitron U, 2014. Cross-sectional study of the burden of vector-borne and soil-transmitted polyparasitism in rural communities of Coast Province, Kenya. PLoS Negl Trop Dis 8: e2992.
Ansari MZ, Ajani UA, Shope RE, 1993. Diagnosis of viruses by immunoassays. Asian Pac J Allergy Immunol 11: 167–175.
Simmons M, Nelson WM, Wu SJ, Hayes CG, 1998. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58: 655–662.
Thein S, Aaskov J, Myint TT, Shwe TN, Saw TT, Zaw A, 1993. Changes in levels of anti-dengue virus IgG subclasses in patients with disease of varying severity. J Med Virol 40: 102–106.
Pond WL, Ehrenkranz NJ, Danauskas JX, Carter MJ, 1967. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue. J Immunol 98: 673–682.
Ledermann JP, Lorono-Pino MA, Ellis C, Saxton-Shaw KD, Blitvich BJ, Beaty BJ, Bowen RA, Powers AM, 2011. Evaluation of widely used diagnostic tests to detect West Nile virus infections in horses previously infected with St. Louis encephalitis virus or dengue virus type 2. Clin Vaccine Immunol 18: 580–587.
Wisseman CL Jr, Kitaoka M, Tamiya T, 1966. Immunological studies with group B arthropod-borne viruses. V. Evaluation of cross-immunity against type 1 dengue fever in human subjects convalescent from subclinical natural Japanese encephalitis virus infection and vaccinated with 17D strain yellow fever vaccine. Am J Trop Med Hyg 15: 588–600.
Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, Zhu QY, Qin ED, Guo YJ, Qin CF, 2011. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 6: e16059.
Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV, 2002. Short report: absence of protective neutralizing antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg 66: 115–116.
Sanders EJ, Marfin AA, Tukei PM, Kuria G, Ademba G, Agata NN, Ouma JO, Cropp CB, Karabatsos N, Reiter P, Moore PS, Gubler DJ, 1998. First recorded outbreak of yellow fever in Kenya, 1992–1993. I. Epidemiologic investigations. Am J Trop Med Hyg 59: 644–649.
Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, Ahmed R, Suthar MS, Wrammert J, 2016. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 113: 7852–7857.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||745||342||6|
Dengue virus (DENV) and West Nile virus (WNV) are important reemerging arboviruses that are under-recognized in many parts of Africa due to lack of surveillance. As a part of a study on flavivirus, alphavirus, and parasite exposure in coastal Kenya, we measured neutralizing antibody against DENV and, to evaluate assay specificity, WNV in serum samples that tested positive for serum anti-DENV IgG by enzyme-linked immunosorbent assay. Of 830 anti-DENV IgG-positive samples that were tested for neutralizing activity, 488 (58.8%) neutralized DENV and 94 (11.3%) neutralized WNV. Of children ≤ 10 years of age, 23% and 17% had serum neutralizing antibody to DENV and WNV, respectively, indicating that DENV and WNV transmission has occurred in this region within the past decade. The results suggest that ongoing DENV and WNV transmission continues on the coast of Kenya and supports a need for routine arboviral surveillance in the area to detect and respond to future outbreaks.
Authors' addresses: David M. Vu and A. Desiree LaBeaud, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, E-mails: firstname.lastname@example.org and email@example.com. Tamara Banda, Crystal Y. Teng, Chelsea Heimbaugh, Julie Brichard, and Ginny Gildengorin, Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA, E-mails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Eric M. Muchiri, Division of Vector Borne and Neglected Diseases, Ministry of Public Health and Sanitation, Nairobi, Kenya, E-mail: email@example.com. Peter L. Mungai and Charles H. King, Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, E-mails: firstname.lastname@example.org and email@example.com. Francis M. Mutuku and Uriel Kitron, Department of Environmental Studies, Emory University, Atlanta, GA, E-mails: firstname.lastname@example.org and email@example.com. Erin M. Borland and Ann M. Powers, Division of Vector-borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, E-mails: firstname.lastname@example.org and email@example.com.